Forte Biosciences, Inc.
5
3
3
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
20.0%
1 terminated/withdrawn out of 5 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
Role: lead
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Role: lead
Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease
Role: lead
Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study
Role: lead
Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis
Role: lead
All 5 trials loaded